Trial reportJournal of the American Society of Nephrology : JASN2011
Use of aspirin associates with longer primary patency of hemodialysis grafts.
Trial report in Journal of the American Society of Nephrology : JASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Antiplatelet agents for chronic kidney disease.The Cochrane database of systematic reviews · 2022Pooled it
- Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.The Cochrane database of systematic reviews · 2021Pooled it
- Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.BMC nephrology · 2019Pooled it
- Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.The Cochrane database of systematic reviews · 2015Pooled it
- The outcomes of a novel two-stage proximal brachial artery to proximal basilic/brachial vein arteriovenous graft extension for dialysis access.The journal of vascular access · 2023Article
- Role of Antiplatelet Therapy in Hemodialysis Arteriovenous Graft Secondary Patency Following Successful Percutaneous Thrombectomy.Cardiovascular and interventional radiology · 2023Article
- Temporal regulation of notch activation improves arteriovenous fistula maturation.Journal of translational medicine · 2022Article
- Notch signaling in bone marrow-derived FSP-1 cells initiates neointima formation in arteriovenous fistulas.Kidney international · 2019Article
- The Effect of Aspirin on Preventing Vascular Access Dysfunction in Incident Hemodialysis Patients: A Prospective Cohort Study in Korean Clinical Research Centers for End-Stage Renal Disease (CRC for ESRD).Journal of clinical medicine · 2019Article
- Role of antiplatelet therapy in the durability of hemodialysis access.Journal of nephrology · 2018Article
- An Increase in Mean Platelet Volume/Platelet Count Ratio Is Associated with Vascular Access Failure in Hemodialysis Patients.PloS one · 2017Article
- Assessment of Novel Anti-thrombotic Fusion Proteins for Inhibition of Stenosis in a Porcine Model of Arteriovenous Graft.PloS one · 2015Article
- Vascular access choice in incident hemodialysis patients: a decision analysis.Journal of the American Society of Nephrology : JASN · 2015Article
- Chronic kidney disease accelerates endothelial barrier dysfunction in a mouse model of an arteriovenous fistula.American journal of physiology. Renal physiology · 2013Article
- Thrombophilia and arteriovenous fistula survival in ESRD.Clinical journal of the American Society of Nephrology : CJASN · 2013Observational
- Vascular access today.World journal of nephrology · 2012Review
Corrections and comments
- Commented on by
Authors and funding
19 authors at 12 institutions in 1 country.
Funding
Abstract
Extended-release dipyridamole plus low-dose aspirin (ERDP/ASA) prolongs primary unassisted graft patency of newly created hemodialysis arteriovenous grafts, but the individual contributions of each component are unknown. Here, we analyzed whether use of aspirin at baseline associated with primary unassisted graft patency among participants in a randomized trial that compared ERDP/ASA and placebo in newly created grafts. We used Cox proportional hazards regression, adjusting for prespecified baseline comorbidities and covariates. Of all participants, 43% reported use of aspirin at baseline; of these, 82% remained on nonstudy aspirin (i.e., excluding ERDP/ASA) at 1 year. After 1 year of follow-up, the incidence of primary unassisted patency among participants using aspirin at baseline was 30% (95% CI: 24 to 35%) and among those not using aspirin was 23% (95% CI: 18 to 27%). Use of aspirin at baseline associated with a dose-dependent prolongation of primary unassisted graft patency that approached statistical significance (adjusted HR, 0.83; 95% CI: 0.68 to 1.01; P=0.06). Use of aspirin at baseline did not associate with prolongation of cumulative graft patency or participant survival. In conclusion, use of aspirin associates with a trend toward longer primary unassisted patency of newly placed hemodialysis grafts similar to that observed for ERDP/ASA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.